| Keywords: |
treatment response; unclassified drug; hepatitis; drug dose reduction; nonhuman; treatment duration; note; drug megadose; neoplasm; neoplasms; cd8+ t lymphocyte; lymphocyte proliferation; t lymphocyte; t-lymphocytes; ipilimumab; cancer immunotherapy; melanoma; editorial; tumor regression; kidney carcinoma; monoclonal antibody; immunology; antibodies, monoclonal; cellular immunity; immunotherapy; cancer vaccine; nonsteroid antiinflammatory agent; cd4+ t lymphocyte; corticosteroid derivative; tumor immunity; autoimmunity; dermatitis; antigens, cd; peptide vaccine; cytotoxic t lymphocyte antigen 4; leukocyte antigen; adoptive immunotherapy; immunotherapy, adoptive; t lymphocyte activation; b7 antigen; antigens, differentiation; differentiation antigen; enterocolitis; uveitis; immunity, cellular; antigens, cd80; cytotoxic t-lymphocyte antigen 4; hypophysitis; vitiligo; monoclonal antibody ctla 4; infliximab; vaccinia vaccine
|
